- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07410117
REGN7508 bei erwachsenen Teilnehmern zur Prävention von Krebs-assoziierten Thrombosen (ROXI-CAT-I)
Eine Phase-3-, multizentrische, randomisierte, doppelblinde, placebokontrollierte Studie zur Bewertung der Wirksamkeit und Sicherheit von REGN7508, einem monoklonalen Antikörper gegen FXI, zur Primärprophylaxe von krebsassoziierten Thrombosen bei Teilnehmern mit soliden Tumoren, die sich einer Krebsbehandlung unterziehen (ROXI-CAT-I)
This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on the prevention of Cancer-Associated Thrombosis (CAT) in participants.
The aim of the study is to see how effective the study drug is in preventing blood clots in participants with solid tumors who are currently receiving anticancer treatment or planning to start anticancer treatment within a month of being assigned to a study treatment, or recovering from surgery, and how the study drug compares to placebo for CAT.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: Clinical Trials Administrator
- Telefonnummer: 844-734-6643
- E-Mail: clinicaltrials@regeneron.com
Studienorte
-
-
-
Tbilisi, Georgia, 0159
- Rekrutierung
- Institute of Clinical Oncology
-
Tbilisi, Georgia, 0186
- Rekrutierung
- Caucasus Medical Centre
-
Tbilisi, Georgia, 0144
- Rekrutierung
- Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
-
Tbilisi, Georgia, 0179
- Rekrutierung
- LTD Cancer Research Centre
-
Tbilisi, Georgia, 0179
- Rekrutierung
- JSC Evex Hospitals - Caraps Medline
-
Tbilisi, Georgia, 0102
- Rekrutierung
- American Hospital Tbilisi
-
Tbilisi, Georgia, 0112
- Rekrutierung
- Llc Todua Clinic
-
Tbilisi, Georgia, 0112
- Rekrutierung
- Israel Georgia Medical Research Clinic Helsicore
-
-
Adjara
-
Batumi, Adjara, Georgia, 6000
- Rekrutierung
- LTD High Technology Hospital Medcenter
-
-
Imereti
-
Kutaisi, Imereti, Georgia, 4600
- Rekrutierung
- Krystyna Kiel Oncology Center
-
-
-
-
-
Niigata, Japan, 951-8520
- Rekrutierung
- Niigata University Medical & Dental Hospital
-
-
Ehime
-
Tōon, Ehime, Japan, 791-0295
- Rekrutierung
- Ehime University Hospital
-
-
Gunma
-
Ōta, Gunma, Japan, 373-8550
- Rekrutierung
- Gunma Prefectural Cancer Center
-
-
Hyōgo
-
Akashi, Hyōgo, Japan, 673-8558
- Rekrutierung
- Hyogo Cancer Center
-
-
Kagawa-ken
-
Kita-gun, Kagawa-ken, Japan, 761-0793
- Rekrutierung
- Kagawa University Hospital
-
-
Kanagawa
-
Isehara-Shi, Kanagawa, Japan, 259-1193
- Rekrutierung
- Tokai University Hospital
-
-
Kyoto
-
Kyoto, Kyoto, Japan, 602-8566
- Rekrutierung
- University Hospital Kyoto Prefectural University of Medicine
-
-
Miyagi
-
Sendai, Miyagi, Japan, 980-8574
- Rekrutierung
- Tohoku University Hospital
-
-
Osaka
-
Chuo, Osaka, Japan, 540-0006
- Rekrutierung
- National Hospital Organization Osaka National Hospital (ONH)
-
-
Saitama
-
Ina-machi, Saitama, Japan, 362-0806
- Rekrutierung
- Saitama Cancer Center
-
-
Tokyo
-
Chuo Ku, Tokyo, Japan, 104-0045
- Rekrutierung
- National Cancer Center Hospital - Tsukiji Campus
-
Shinjuku, Tokyo, Japan, 160-0023
- Rekrutierung
- Tokyo Medical University Hospital
-
-
Yamaguchi
-
Ube, Yamaguchi, Japan, 755-8505
- Rekrutierung
- Yamaguchi University Hospital
-
-
-
-
Florida
-
Hialeah, Florida, Vereinigte Staaten, 33013
- Rekrutierung
- Bioresearch Partner- Hialeah Hospital
-
North Miami Beach, Florida, Vereinigte Staaten, 33169
- Rekrutierung
- Helios Clinical Research
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Rekrutierung
- Beth Israel Deaconess Medical Center
-
-
New York
-
New York, New York, Vereinigte Staaten, 10021
- Rekrutierung
- Memorial Sloan Kettering Cancer Center
-
-
Texas
-
El Paso, Texas, Vereinigte Staaten, 79902
- Zurückgezogen
- El Paso Medical Research Institute (Medresearch Inc)
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key Inclusion Criteria:
- Has a histologically confirmed diagnosis of malignant solid tumors which are locally advanced or metastatic as described in the protocol
- Has a Khorana thromboembolic risk score ≥2 during screening period or harbors a somatic documented tumor genetic variant known to be associated with a similar increased risk of VTE as described in the protocol
- Has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2 at the time of screening and day 1 prior to the first dose of study intervention
Key Exclusion Criteria:
- Has known bleeding conditions (eg, Hemophilia A or B, von Willebrand's disease), hemorrhagic tumor sites, or other conditions with a high risk for bleeding (eg, hepatic disease associated with coagulopathy)
- Has a cancer diagnosis consisting solely of basal cell or squamous cell skin carcinoma
- Has a primary brain tumor or brain metastases as described in the protocol
- Has proximal lower extremity DVT locally detected by Compression Ultrasound (CUS) during screening period
- Has any condition that, as judged by the investigator, may confound the results of the study or would place the participant at increased risk of harm if he/she participated in the study
Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Placebo-Komparator: Placebo
|
Administered per the protocol |
|
Experimental: REGN7508
|
Administered per the protocol
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Zeit bis zum ersten Ereignis einer zentral bewerteten ISTH-Major-Blutung (International Society of Thrombosis and Hemostasis) oder einer klinisch relevanten Non-Major-Blutung (CRNM)
Zeitfenster: Über 6 Monate
|
Über 6 Monate
|
|
Time-to-first event of centrally adjudicated VTE (DVT, PE) or ATE, or thromboembolism- or ATE-related death
Zeitfenster: Through 6 months
|
Through 6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Auftreten von behandlungsbedingten unerwünschten Ereignissen (TEAEs)
Zeitfenster: Bis Tag 245
|
Bis Tag 245
|
|
Schweregrad der TEAEs
Zeitfenster: Bis Tag 245
|
Bis Tag 245
|
|
Magnitude of ADA to REGN7508
Zeitfenster: Bis zum 245. Tag
|
Bis zum 245. Tag
|
|
Time-to-first event of the centrally adjudicated symptomatic or incidental VTE (DVT, PE) or ATE and thromboembolism- or ATE-related death
Zeitfenster: Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic VTE
Zeitfenster: Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic DVT
Zeitfenster: Through 6 months
|
Through 6 months
|
|
Time-to-first event of symptomatic non-fatal PE
Zeitfenster: Through 6 months
|
Through 6 months
|
|
Time-to-first event of thromboembolism-related death
Zeitfenster: Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental VTE
Zeitfenster: Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental upper extremity or incidental proximal lower extremity DVT
Zeitfenster: Through 6 months
|
Through 6 months
|
|
Time-to-first event of incidental non-fatal PE (in a segmental or larger pulmonary artery)
Zeitfenster: Through 6 months
|
Through 6 months
|
|
Time-to-first event of asymptomatic VTE (Asymptomatic DVT detected by lower extremities ultrasound)
Zeitfenster: Through 6 months
|
Through 6 months
|
|
Time-to-first event of ATE
Zeitfenster: Through 6 months
|
Through 6 months
|
|
Time-to-first event of ATE-related death
Zeitfenster: Through 6 months
|
Through 6 months
|
|
Time-to-first event of centrally adjudicated VTE (DVT, PE), or thromboembolism-related death
Zeitfenster: Through 6 months
|
Through 6 months
|
|
Occurrence of Anti-Drug Antibody (ADA) to REGN7508
Zeitfenster: Up to day 245
|
Up to day 245
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Clinical Trial Management, Regeneron Pharmaceuticals
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- R7508-CAT-2392
- 2024-519298-21-00 (Ctis)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
IPD-Sharing-Zeitrahmen
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD-Sharing-Zugriffskriterien
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ICF
- ANALYTIC_CODE
- CSR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .